Study Findings from Leipzig University Medical Center Advance Knowledge in Chronic Hepatitis B Virus [Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A...].

A recent study conducted by Leipzig University Medical Center in Germany has found that tenofovir alafenamide (TAF) is a safe and effective treatment for chronic hepatitis B (CHB) patients, even in those with decreased renal function. TAF is a prodrug of tenofovir that has shown a favorable renal safety profile while effectively suppressing HBV DNA. The study included 50 patients with CHB who received TAF treatment for an average of 18 months. The results showed a significant decrease in HBV DNA levels and stable renal function throughout the observation period. Mild adverse events were reported by 28% of the patients. This research provides valuable insights into the real-world use of TAF in European patients with CHB. [Extracted from the article]